Stephane Bancel - 01 Jun 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MRNA
Reported as of: 01 Jun 2021
Net transaction value: -$3,684,254
SEC form: 4
Accepted by SEC: 03 Jun 2021, 16:41:00 UTC
Prior SEC filing: 28 May 2021
Next SEC filing: 04 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Brian Sandstrom, as Attorney-in-Fact

Key filing fact

Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 03 Jun 2021.

Key facts

This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
7 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2021, 16:41.

Change

Previous filing in this sequence was filed on 28 May 2021.
Current net transaction value: -$3,684,254.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Sale

Transaction value: $261,904
Shares: -1,443
Change %: -13%
Price: $181.50
Shares after: 9,619
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F1, F2, F3

MRNA transaction

Common Stock

Sale

Transaction value: $383,783
Shares: -2,102
Change %: -22%
Price: $182.58
Shares after: 7,517
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F1, F3, F4

MRNA transaction

Common Stock

Sale

Transaction value: $602,057
Shares: -3,279
Change %: -44%
Price: $183.61
Shares after: 4,238
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F1, F3, F5

MRNA transaction

Common Stock

Sale

Transaction value: $762,882
Shares: -4,138
Change %: -98%
Price: $184.36
Shares after: 100
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F1, F3, F6

MRNA transaction

Common Stock

Sale

Transaction value: $18,527
Shares: -100
Change %: -100%
Price: $185.27
Shares after: 0
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F1, F3

MRNA transaction

Common Stock

Sale

Transaction value: $1,655,100
Shares: -9,000
Change %: -0.14%
Price: $183.90
Shares after: 6,281,868
Date: 02 Jun 2021
Ownership: Direct
Footnotes: F7

MRNA transaction

Common Stock

Gift

Transaction value
Shares: -2,000
Change %: -0.03%
Price
Shares after: 6,279,868
Date: 02 Jun 2021
Ownership: Direct
Footnotes: F8, F9

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7,394,880
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F10

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,050,372
Date: 01 Jun 2021
Ownership: See Footnote
Footnotes: F11

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 11 footnotes

Footnote F1

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $180.93 to $181.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $181.96 to $182.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $183.00 to $184.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.04 to $184.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F7

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

Footnote F8

The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020.

Footnote F9

The reported disposition represents a bona fide charitable gift made by the reporting person.

Footnote F10

These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F11

These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.